Crinetics Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Crinetics Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $84.82. The average 1-year stock price forecast is 1.54% higher than the current stock price, while the lowest is $55 (-34.16%) and the highest is $97 (+16.13%).

Price Target: $84.82 (+1.54%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$55	$84.82	$85	$97
Change	-34.16%	+1.54%	+1.76%	+16.13%

Analyst Ratings

The average analyst rating for Crinetics Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	12	12	12	12	12	9
Buy	3	3	3	3	3	1
Hold	1	1	1	1	1	4
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	16	16	16	16	16	14

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jonathan Wolleben Citizens JMP	Citizens JMP	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Jul 7, 2026
Dennis Ding Jefferies	Jefferies	Hold Downgrades $55 → $85	Hold	Downgrades	$55 → $85	+1.76%	Jul 7, 2026
Catherine Novack JonesTrading	JonesTrading	Hold Downgrades $97 → $85	Hold	Downgrades	$97 → $85	+1.76%	Jul 7, 2026
Kate Dellorusso LifeSci Capital	LifeSci Capital	Hold Reiterates $85	Hold	Reiterates	$85	+1.76%	Jul 7, 2026
Yasmeen Rahimi Piper Sandler	Piper Sandler	Hold Downgrades n/a	Hold	Downgrades	n/a	n/a	Jul 7, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

68.81M

from 7.70M

794.07%

from 7.70M

Revenue Next Year

173.06M

from 68.81M

151.51%

from 68.81M

EPS This Year

-4.75

from -4.95

EPS Next Year

-4.15

from -4.75

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	1.08M	4.74M	4.01M	1.04M	7.70M	68.81M
Revenue Growth	1,418.31%	339.43%	-15.28%	-74.11%	640.71%	794.07%
Operating Income	-107.70M	-167.88M	-222.61M	-338.85M	-516.77M	-538.84M
Net Income	-107.64M	-163.92M	-214.53M	-298.41M	-465.32M	-511.97M
EPS	-	-	-	-	-4.95	-4.75
Free Cash Flow	-48.47M	-62.51M	-93.53M	-136.41M	-206.91M	-417.67M
No. Analysts	-	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	76.1M
Avg	68.8M
Low	57.7M

Revenue Growth

Revenue Growth	2026	2027	2028
High	888.6%
Avg	794.1%
Low	650.2%

EPS Forecast

EPS	2026	2027	2028
High	-3.87
Avg	-4.75
Low	-5.28

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-